Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer

References

• De Wit R, De Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506–2518.
   PubMed Web of Science ®Google Scholar
• De Bono J, Mateo J, Fizazi K, et al., Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 382(22): 2091–2102. 2020;
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Maughan BL, Luber B, Nadal R, et al. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate. 2017;77(1):33–40.
   PubMed Web of Science ®Google Scholar
• Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20(12):1730–1739.
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008 Mar;8(3):193–204.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374.
   PubMedGoogle Scholar
• Mateo J, Carreira S, Sandhu S, et al., DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 373(18): 1697–1708. 2015;
   PubMed Web of Science ®Google Scholar
• Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162–174.
   PubMed Web of Science ®Google Scholar
• Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383(24):2345–2357.
   Web of Science ®Google Scholar
• Abida W, Patnaik A, Campbell D, et al., Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. J Clin Oncol. 38(32): JCO2001035. 2020. .
   Web of Science ®Google Scholar
• Markowski MC, Antonarakis ES. BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: more Different Than Alike? J Clin Oncol. 2020;38(32):JCO2002246.
   Web of Science ®Google Scholar
• Abida W, Campbell D, Patnaik A, et al. Non-BRCA DNA damage repair gene alterations and response to the parp inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res. 2020;26(11):2487–2496.
   PubMed Web of Science ®Google Scholar
• Marshall CH, Sokolova AO, McNatty AL, et al., Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur Urol. 76(4): 452–458. 2019;
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Velho PI, Fu W, et al. CDK12 -Altered Prostate Cancer: clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol. 2020;4(4):370–381.
   PubMedGoogle Scholar
• Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Mar;18: S1470–2045(21)00073–5.
   Google Scholar
• Antonarakis ES. Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer. N Engl J Med. 2018;379(11):1087–1089.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Gomella LG, Petrylak DP. When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials. Eur Urol Oncol. 2020 Oct;3(5):594–611.
   PubMed Web of Science ®Google Scholar
• Marshall CH, Fu W, Wang H, et al. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59–65.
   PubMed Web of Science ®Google Scholar
• Abeshouse A, Ahn J, Akbani R, Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015 Nov 5;163(4):1011–1025.
   PubMed Web of Science ®Google Scholar
• Pettitt SJ, Frankum JR, Punta M, et al. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 2020;10(10):1475–1488.
   PubMed Web of Science ®Google Scholar
• Gourley C, Balmana J, Ledermann JA, et al. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. J Clin Oncol. 2019;37(25):2257–2269.
   PubMed Web of Science ®Google Scholar
• Rafiei S, Fitzpatrick K, Liu D, et al. ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer. Cancer Res. 2020;80(11):2094–2100.
   PubMed Web of Science ®Google Scholar
• Am W, Siemeister G, Lucking U, et al. The novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or repair-compromising therapies in preclinical cancer models. Mol Cancer Ther. 2020;19(1):26–38.
   PubMed Web of Science ®Google Scholar